Lenvatinib 4 Mg Tablet | Jasgur Life Sciences
Lenvatinib is FDA-approved for the treatment of radioactive iodine-refractory differentiated thyroid cancer (DTC), unresectable or advanced hepatocellular carcinoma (HCC), and advanced renal cell carcinoma (RCC). It is a multiple receptor tyrosine kinase inhibitor that demonstrates potent antiangiogenic properties.
https://jasgurlifescience.com/oncology/lenvabuzz
https://jasgurlifescience.com
Like
Comment
Share
